Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D

Andrew Dunn

Senior Biopharma Correspondent

Ryan Cross

Senior Science Correspondent

A star-studded mix of venture capitalists and scientists, backed by more than a billion dollars, is launching an ambitious biotech that aims to reinvent drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D

Andrew Dunn

Senior Biopharma Correspondent

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

The brain is Eli Lilly's next target for its obesity meds

The Endpoints 100: The biotech industry braces for Trump 2.0

During Covid, RFK Jr. lobbied against vaccine EUAs for children. As HHS secretary, he could rescind them

Candel’s shares soar on Phase 3 prostate cancer data despite unclear prospects

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

The key to faster, more impactful research? Put patients in the driver’s seat

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

Senior Biopharma Correspondent

Senior Science Correspondent

Sign up to read this article for free.

Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D